Verapamil (versus unexposed)

Caesarean

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17162
R71976		 Vaclavik - Verapamil, 2024 Caesarean section during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 1.76 [1.21;2.55] -/43   -/252,856 - 43
ref
Total 1 studies 1.76 [1.21;2.55] 0 43
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Vaclavik - Verapamil, 2024Vaclavik - Verapamil, 2024 1.76[1.21; 2.55]-430%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: unclear0.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.76[1.21; 2.55]-43 -NAVaclavik - Verapamil, 2024 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.76[1.21; 2.55]-43 -NAVaclavik - Verapamil, 2024 1 Tags Adjustment   - No  - No 1.76[1.21; 2.55]-43 -NAVaclavik - Verapamil, 2024 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 1.76[1.21; 2.55]-43 -NAVaclavik - Verapamil, 2024 1 All studiesAll studies 1.76[1.21; 2.55]-43 -NAVaclavik - Verapamil, 2024 10.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.76[1.21; 2.55]-43 -NAVaclavik - Verapamil, 2024 10.510.01.0